open access

Vol 49, No 2 (2018)
ORIGINAL RESEARCH ARTICLE
Published online: 2018-08-30
Submitted: 2016-09-18
Get Citation

Clinical and laboratory features of Adult T-cell Leukemia/lymphoma (ATL): a study of 37 cases

Cristiane da de Araújo, Mirna Maira Carmo, Claudia de Maximo, Sílvia Maia de Carvalho
DOI: 10.2478/ahp-2018-0014
·
Acta Haematol Pol 2018;49(2):75-84.

open access

Vol 49, No 2 (2018)
ORIGINAL RESEARCH ARTICLE
Published online: 2018-08-30
Submitted: 2016-09-18

Abstract

Adult T-cell leukemia/lymphoma (ATL) related to the human T-cell lymphotropic virus type I (HTLV-I) is a malignant lymphoproliferative disease. ATL is classified in four subtypes: lymphoma, acute, smoldering and chronic. We analyzed, retrospectively, 46 consecutive patients with T-cell disease with ATL diagnosed from 1995 to 2007. ATL diagnose was confirmed in 37 of these patients. There were 26 females and 11 males (70% vs 30%, respectively, p=0.014). The median age was 42 years old. Twenty-five were nonwhite and twelve were white (67.6% vs 32.4%, respectively, p=0.033).Twenty two patients had the acute form, eight had chronic form and seven had lymphomatous form. Two of them had osteolytic lesions. There were two cases with pulmonary infiltrates; one patient had ATL associated to Hansen’s disease. All cases had antibodies to HTLV-I confirmed by Western Blot, polymerase chain reaction (PCR) was performed in 22 cases. Flow cytometry revealed positivity for CD4 and CD25 in most cases. The mean and median overall survival time was 11.3 months and 2 months, respectively. The family´s study showed that 60% of the mothers were HTLV-I seropositive. These data emphasize the importance of a serologic screening for HTLV and immunophenotyping to differentiate ATL from others T-lymphoproliferative disorders.

Abstract

Adult T-cell leukemia/lymphoma (ATL) related to the human T-cell lymphotropic virus type I (HTLV-I) is a malignant lymphoproliferative disease. ATL is classified in four subtypes: lymphoma, acute, smoldering and chronic. We analyzed, retrospectively, 46 consecutive patients with T-cell disease with ATL diagnosed from 1995 to 2007. ATL diagnose was confirmed in 37 of these patients. There were 26 females and 11 males (70% vs 30%, respectively, p=0.014). The median age was 42 years old. Twenty-five were nonwhite and twelve were white (67.6% vs 32.4%, respectively, p=0.033).Twenty two patients had the acute form, eight had chronic form and seven had lymphomatous form. Two of them had osteolytic lesions. There were two cases with pulmonary infiltrates; one patient had ATL associated to Hansen’s disease. All cases had antibodies to HTLV-I confirmed by Western Blot, polymerase chain reaction (PCR) was performed in 22 cases. Flow cytometry revealed positivity for CD4 and CD25 in most cases. The mean and median overall survival time was 11.3 months and 2 months, respectively. The family´s study showed that 60% of the mothers were HTLV-I seropositive. These data emphasize the importance of a serologic screening for HTLV and immunophenotyping to differentiate ATL from others T-lymphoproliferative disorders.

Get Citation

Keywords

HTLV-I; ATL; Clinical characteristics; Brazil

About this article
Title

Clinical and laboratory features of Adult T-cell Leukemia/lymphoma (ATL): a study of 37 cases

Journal

Acta Haematologica Polonica

Issue

Vol 49, No 2 (2018)

Pages

75-84

Published online

2018-08-30

DOI

10.2478/ahp-2018-0014

Bibliographic record

Acta Haematol Pol 2018;49(2):75-84.

Keywords

HTLV-I
ATL
Clinical characteristics
Brazil

Authors

Cristiane da de Araújo
Mirna Maira Carmo
Claudia de Maximo
Sílvia Maia de Carvalho

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl